RIM
ADAP

RS Investment Management’s Adaptimmune Therapeutics ADAP Stock Holding History

RS Investment Management’s Portfolio ADAP Stock Details ADAP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q2 		$513K Hold
62,980
– – 0.01% 340
2016
Q1 		$512K Hold
62,980
– – 0.01% 338
2015
Q4 		$760K Buy
+62,980
New +$617K 0.01% 300

Other funds holding ADAP

NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
FCMI
Foresite Capital Management II Larkspur, California $29.2M AUM 44.84% 1-Year Est. Return
QF
QVT Financial New York $1.37B AUM 148.1% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
Fidelity International
Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

RS Investment Management's ADAP Position: Q2 2016 in Review

RS Investment Management held its Adaptimmune Therapeutics (ADAP) position steady in Q2 2016 at 62,980 shares worth $513K. The position accounts for 0.01% of the portfolio, ranked #340.

RS Investment Management first reported a position in ADAP in Q4 2015 and has held it in 3 quarters since. The position peaked at $760K in Q4 2015. 47 funds tracked by Wall St. Rank hold ADAP as of Q2 2016.

  • RS Investment Management held 62,980 shares of Adaptimmune Therapeutics worth $513K as of Q2 2016.
  • RS Investment Management left its Adaptimmune Therapeutics share count unchanged in Q2 2016.
  • Adaptimmune Therapeutics made up 0.01% of RS Investment Management's portfolio in Q2 2016, its #340 holding.
  • RS Investment Management first reported a position in Adaptimmune Therapeutics in Q4 2015 and has held it in 3 quarters since.
  • RS Investment Management's Adaptimmune Therapeutics position peaked at $760K in Q4 2015.
  • 47 funds tracked by Wall St. Rank held Adaptimmune Therapeutics as of Q2 2016.

Based on RS Investment Management's 13F filing for Q2 2016, filed 26 Jul 2016.